Aptevo Therapeutics Inc (APVO)

$0.93 -0.09 (-8.81%)
Market Cap 17.19M
Revenue (ttm) 0.00
Net Income (ttm) -24.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 910,400
Avg Vol 929,900
Day's Range N/A - N/A
Shares Out 16.85M
Stochastic %K 8%
Beta 1.41
Analysts Sell
Price Target $21.00

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 838 0500
Fax: 206 838 0503
Address:
2401 4th Avenue, Suite 1050, Seattle, United States
BackstopBets
BackstopBets Dec. 25 at 7:56 AM
$APVO The valuation debate now centers on reliability of delivery, since capital markets reward discipline over expansion for its own sake. The upside case requires evidence, not projection.
0 · Reply
Felixii
Felixii Dec. 24 at 10:04 PM
$APVO i think it will touch the trendchannel first before a squeeze could happen
0 · Reply
ONLYPHARMS
ONLYPHARMS Dec. 24 at 6:30 PM
$APVO tax selling? hope not atm at this price
0 · Reply
Felixii
Felixii Dec. 24 at 5:46 PM
$APVO the news are to good on this one, something to the upside will happen i am very sure
0 · Reply
Felixii
Felixii Dec. 24 at 5:18 PM
$APVO shake out before run
0 · Reply
LossSporn
LossSporn Dec. 24 at 4:41 PM
$APVO 🗑️
0 · Reply
itsMeRich
itsMeRich Dec. 24 at 4:33 PM
$APVO SAC probably effing with it…. They’re a POS…..
0 · Reply
elmono
elmono Dec. 24 at 4:28 PM
$APVO dirty hedge fund not playing nice…turd ceo not buying his own meds
0 · Reply
elmono
elmono Dec. 24 at 4:21 PM
$APVO painful to see this fall back to 50s
0 · Reply
Bgreen999
Bgreen999 Dec. 24 at 3:58 PM
$APVO .94 greasy
0 · Reply
Latest News on APVO
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Dec 9, 2025, 8:05 AM EST - 16 days ago

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Nov 10, 2025, 8:05 AM EST - 6 weeks ago

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Nov 6, 2025, 8:05 AM EST - 7 weeks ago

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Oct 8, 2025, 8:20 AM EDT - 2 months ago

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 16, 2025, 8:30 AM EDT - 3 months ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Sep 4, 2025, 8:45 AM EDT - 4 months ago

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 13, 2025, 8:05 AM EDT - 4 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aug 11, 2025, 8:05 AM EDT - 4 months ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 11:30 AM EDT - 6 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:55 AM EDT - 6 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 20, 2025, 8:01 AM EDT - 6 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 1:34 PM EDT - 6 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 11:37 AM EDT - 6 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 10:52 AM EDT - 6 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 18, 2025, 8:01 AM EDT - 6 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Aptevo Participating in the BIO International Convention

Jun 13, 2025, 8:05 AM EDT - 6 months ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 22, 2025, 8:05 AM EDT - 7 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 15, 2025, 8:05 AM EDT - 8 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

May 8, 2025, 8:45 AM EDT - 8 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 22, 2025, 4:05 PM EDT - 8 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 8 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 9 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 9 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 20, 2025, 8:35 AM EDT - 10 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 18, 2025, 8:05 AM EDT - 10 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Aptevo to Participate in March Conferences

Mar 6, 2025, 8:00 AM EST - 10 months ago

Aptevo to Participate in March Conferences

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 15, 2025, 6:59 PM EST - 11 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Feb 14, 2025, 8:05 AM EST - 11 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Jan 15, 2025, 8:00 AM EST - 1 year ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 12:50 PM EST - 1 year ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 12, 2024, 9:00 AM EST - 1 year ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Dec 4, 2024, 8:35 AM EST - 1 year ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 29, 2024, 9:55 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 26, 2024, 8:35 AM EST - 1 year ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 22, 2024, 8:35 AM EST - 1 year ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 20, 2024, 8:35 AM EST - 1 year ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 11, 2024, 8:15 AM EST - 1 year ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Nov 7, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 14, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

May 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Aptevo Therapeutics Provides Pipeline Update

Apr 10, 2024, 9:00 AM EDT - 1 year ago

Aptevo Therapeutics Provides Pipeline Update

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Mar 18, 2024, 6:00 AM EDT - 1 year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

BackstopBets
BackstopBets Dec. 25 at 7:56 AM
$APVO The valuation debate now centers on reliability of delivery, since capital markets reward discipline over expansion for its own sake. The upside case requires evidence, not projection.
0 · Reply
Felixii
Felixii Dec. 24 at 10:04 PM
$APVO i think it will touch the trendchannel first before a squeeze could happen
0 · Reply
ONLYPHARMS
ONLYPHARMS Dec. 24 at 6:30 PM
$APVO tax selling? hope not atm at this price
0 · Reply
Felixii
Felixii Dec. 24 at 5:46 PM
$APVO the news are to good on this one, something to the upside will happen i am very sure
0 · Reply
Felixii
Felixii Dec. 24 at 5:18 PM
$APVO shake out before run
0 · Reply
LossSporn
LossSporn Dec. 24 at 4:41 PM
$APVO 🗑️
0 · Reply
itsMeRich
itsMeRich Dec. 24 at 4:33 PM
$APVO SAC probably effing with it…. They’re a POS…..
0 · Reply
elmono
elmono Dec. 24 at 4:28 PM
$APVO dirty hedge fund not playing nice…turd ceo not buying his own meds
0 · Reply
elmono
elmono Dec. 24 at 4:21 PM
$APVO painful to see this fall back to 50s
0 · Reply
Bgreen999
Bgreen999 Dec. 24 at 3:58 PM
$APVO .94 greasy
0 · Reply
elmono
elmono Dec. 24 at 3:33 PM
$APVO scammy HF is destroying SP…..probably go to 50 cts & r/s. I bet active use of ATM to
0 · Reply
RedDogSailor
RedDogSailor Dec. 24 at 3:26 PM
$APVO This is a BO candidate, hence to downward pressure
0 · Reply
elmono
elmono Dec. 24 at 2:41 PM
$APVO turd breakdown…new r/s on its way….never put money in bio zombies with scammy CEO’s that bed doggy HF’s 😂😂😂
0 · Reply
elmono
elmono Dec. 23 at 6:09 PM
$APVO soon out of compliance thanks to one of the more scammy ceo’s in bio zombie land 🤷‍♂️🙏😂….the only thing tutd knows is how to receive fat pay checks, do doggy raises , and destroy shareholder value. Never achieved buy in from reputable bio funds and without treacherous warrant ploys….
1 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 5:05 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 my profits in to $ATCH $OPEN $LASE $APVO X
0 · Reply
FaresM9
FaresM9 Dec. 23 at 3:52 PM
$TIVC $APVO
0 · Reply
pandapanic
pandapanic Dec. 22 at 6:24 PM
$APVO chart looks like a cat waving, and that makes me happy despite the continued wait lol
0 · Reply
Felixii
Felixii Dec. 22 at 3:49 PM
$APVO this will make a huge move once it gets the momentum
0 · Reply
pandapanic
pandapanic Dec. 22 at 3:04 PM
$APVO
0 · Reply
KangaroooJack
KangaroooJack Dec. 22 at 1:39 PM
$APVO welp this never worked out
0 · Reply
Felixii
Felixii Dec. 22 at 9:32 AM
$APVO
0 · Reply
DonZulu
DonZulu Dec. 19 at 8:06 PM
$APVO sitting at bottom adding for a january -feb move
0 · Reply